UniPharma Co., Ltd. (6621.TWO)

13.10 +0.75 (+6.07%) At close: 02:59PM CST

UniPharma Co., Ltd.

No.17, Lane 171
3rd Floor Section 2, Jiu Zong Road NeiHu District
Taipei 11494
Taiwan
886 2 2658 2577
https://www.uni-pharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Yu-Shan Wang Ph.D.	General Manager	N/A	N/A	N/A
Troy Lu	Financial Manager	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was incorporated in 1998 and is based in Taipei, Taiwan.

Corporate governance

UniPharma Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.